Overview

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

Status:
Completed
Trial end date:
2023-10-03
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, randomized study to assess the plasma pharmacokinetic profile of LNZ101 and LNZ100.
Phase:
Phase 1
Details
Lead Sponsor:
LENZ Therapeutics, Inc
Collaborator:
ORA, Inc.
Treatments:
Aceclidine
Brimonidine Tartrate